간행물

대한간암학회> 대한간암학회지

대한간암학회지 update

Journal of liver cancer

  • : 대한간암학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • :
  • : 연속간행물
  • : 반년간
  • : 2288-8128
  • : 2283-5001
  • : 대한간암연구회지(~2010)→대한간암연구학회지(2011~)

수록정보
수록범위 : 1권0호(2001)~20권1호(2020) |수록논문 수 : 492
대한간암학회지
20권1호(2020년 03월) 수록논문
최근 권호 논문
| | | |

KCI등재

1Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma

저자 : Su Jong Yu , Tim F. Greten

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 1-16 (16 pages)

다운로드

(기관인증 필요)

초록보기

Use of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) has been partially successful. However, most HCC patients do not respond to immunotherapy. HCC has been shown to induce several immune suppressor mechanisms in patients. These suppressor mechanisms include involvement of myeloid-derived suppressor cells, regulatory T-cells, functionally impaired dendritic cells (DCs), neutrophils, monocytes, and tumor associated macrophages. The accumulation of immunosuppressive cells may lead to an immunosuppressive tumor microenvironment as well as the dense fibrotic stroma which may contribute to immune tolerance. Our laboratory has been investigating different cellular mechanisms of immune suppression in HCC patients. In vitro as well as in vivo studies have demonstrated that abrogation of the suppressor cells enhances or unmasks tumor-specific antitumor immune responses. Two or three effective systemic therapies including ICIs and/or molecular targeted therapies and the addition of innovative combination therapies targeting immune suppressor cells may lead to increased immune recognition with a greater tumor response. We reviewed the literature for the latest research on immune suppressor cells in HCC, and here we provide a comprehensive summary of the recent studies in this field. (J Liver Cancer 2020;20:1-16)

KCI등재

2Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors

저자 : Haeryoung Kim , Mi Jang , Young Nyun Park

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 17-24 (8 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) is heterogeneous in pathogenesis, phenotype and biological behavior. Various histopathological features of HCC had been sporadically described, and with the identification of common molecular alterations of HCC and its genomic landscape over the last decade, morpho-molecular correlation of HCC has become possible. As a result, up to 35% of HCCs can now be classified into histopathological variants, many of which have unique molecular characteristics. This review will provide an introduction to the variously described histopathological variants of HCC in the updated WHO Classification of Digestive System Tumors. (J Liver Cancer 2020;20:17-24)

KCI등재

3Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Sur-veillance

저자 : So Hyun Park , Bohyun Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 25-31 (7 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) surveillance is recommended when the annual incidence of HCC exceeds 1.5%. In 2018, several international guidelines included alternative surveillance modalities, such as computed tomography and magnetic resonance imaging (MRI), as alternatives for patients with inadequate surveillance with an ultrasound. Currently, abbreviated MRI selectively includes several key sequences and is emerging as an effective tool for HCC surveillance with reduced cost and scan time and the required diagnostic performance. The incidence of HCC substantially impacts the benefits of surveillance in terms of cost-effectiveness. Therefore, we need to individualize imaging surveillance of HCC, tailor screening, and determine risk-stratified strategies. The purpose of this article was to present a brief overview of the diagnostic performance and cost-effectiveness of liver MRI as an HCC surveillance tool. (J Liver Cancer 2020;20:25-31)

KCI등재

4Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma

저자 : Jun Seok , Ki Tae Suk

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 32-40 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer and the fifth leading cause of worldwide cancer mortality. Though early diagnosis of HCC is important, so far lack of effective biomarkers for early diagnosis of HCC has been a problem. In this study, we searched for potential functional biomarkers of alcoholic HCC by using metagenomics approach.
Methods: Between September 2017 and April 2019, normal control (n=44), alcoholic liver cirrhosis (n=44), and alcoholic HCC (n=13) groups were prospectively enrolled and analyzed. Gut microbiota was analyzed using the 16S-based microbiome taxonomic profiling platform of EzBioCloud Apps and analyzing system.
Results: There was a statistically significant difference among groups in diversity (P<0.05). In the comparison of phylum between cirrhosis and HCC, Proteobacteria were increased and Bacteroidetes were decreased. Firmicutes were not significantly different among the three groups. In the taxonomic profiling, relative abundance of Lactobacillus in the cirrhosis and HCC groups showed richness (P<0.05). In the biomarker analysis between cirrhosis and HCC, obiquinome Fe-S protein 3, global nitrogen regulator, Vesicle-associated membrane protein 7, toxin YoeB, peroxisome-assembly ATPase, and nitrogen oxide reductase regulator were differently expressed (P<0.001).
Conclusions: Alcoholic HCC showed different expressions in the stool taxonomy and biomarker compared with that of cirrhosis and control. Therefore, new biomarkers using stool analysis for alcoholic HCC are necessary. (J Liver Cancer 2020;20:32-40)

KCI등재

5Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry

저자 : Jun Sik Yoon , Han Ah Lee , Jun Yong Park , Bo Hyun Kim , In Joon Lee , Young Eun Chon , Suk Kyun Hong , Dong Hyeon Lee , Hyun-joo Kong , Young-joo Won , Eunyang Kim , Jeong-hoon Lee

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 41-52 (12 pages)

다운로드

(기관인증 필요)

초록보기

Backgrounds/Aims: Backgrounds/Aims: In Korea, hepatocellular carcinoma (HCC) is the sixth most common cancer and results in the second-highest cancer death rate among all cancers. We aimed to describe the characteristics of patients who were newly diagnosed with HCC in Korea between 2008 and 2011.
Methods: The Korean Primary Liver Cancer Registry (KPLCR) is a random sample consisting of approximately 15% of patients with newly diagnosed primary liver cancer registered in the Korean Central Cancer Registry. We investigated the baseline characteristics, treatment modalities, and overall survival (OS) of patients with HCC registered in the KPLCR between 2008 and 2011.
Results: A total of 6,083 patients were histologically or radiologically diagnosed with HCC. The hepatitis B virus was the predominant HCC etiology (72.0%). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, stages 0, A, B, C, and D accounted for 8.6%, 39.7%, 11.5%, 33.8%, and 6.9%, respectively. Transarterial therapy (41.7%) was the most commonly performed initial treatment, followed by best supportive care (21.7%), surgical resection (16.7%), and local ablation therapies (10.6%). The overall rate of adherence to the BCLC treatment guideline was only 37.7%. The 1-, 3-, and 5-year OS rates were 65.6%, 46.2%, and 36.8%, respectively.
Conclusions: Between 2008 and 2011, approximately half of patients with HCC (48.3%) were candidates for curative treatment (BCLC stage 0 or A), but one-third of patients (33.8%) had advanced HCC (BCLC stage C). Transarterial therapy was the most commonly conducted initial treatment and the 5-year OS rate was 36.8% in this period. (J Liver Cancer 2020;20:41-52)

KCI등재

6A Survey of Liver Cancer Specialists' Views on the National Liver Cancer Screening Program in Korea

저자 : Won Sohn , Young-sun Lee , Jae Geun Lee , Jihyun An , Eun Sun Jang , Dong Ho Lee , Dong Hyun Sinn

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 53-59 (7 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: To reduce the cancer burden, the Korean government initiated the National Cancer Control Plan including the National Liver Cancer Screening Program (NLCSP). Ultrasonography examinations and α-fetoprotein tests at six-month intervals are currently offered for high-risk individuals. High-risk individuals are identified by reviewing the National Health Insurance Service claims data for medical use for the past two years using International Classification of Diseases Codes for specific liver disease. We surveyed the attitudes and opinions towards the NLCSP to understand the issues surrounding the NLCSP in Korea.
Methods: Altogether, 90 Korean Liver Cancer Association members participated in online and offline surveys between November and December 2019.
Results: Approximately one-quarter (27%) of the survey participants rated the NLCSP as very contributing and about two-thirds (68%) as contributing to some extent toward reducing hepatocellular carcinoma (HCC)-related deaths in Korea. Most (87.8%) responded that the current process of identifying high-risk individuals needs improvement. Many (78.9%) were concerned that the current process identifies individuals who use medical services and paradoxically misses those who do not. When asked for the foremost priority for improvement, solving 'duplication issues between the NLCSP and private clinic HCC screening practices' was the most commonly selected choice (23.3%).
Conclusions: The survey participants positively rated the role of the NLCSP in reducing liver cancer deaths. However, many participants rated the NCLSP as needing improvement in all areas. This survey can be a relevant resource for future health policy decisions regarding the NLCSP in Korea. (J Liver Cancer 2020;20:53-59)

KCI등재

7Lipiodol Pneumonitis Following Transcatheter Arterial Chemoemboliza-tion for Hepatocellular Carcinoma

저자 : Sungkeun Kim , Hee Yeon Kim , Su Lim Lee , Young Mi Ku , Yoo Dong Won , Chang Wook Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 60-66 (7 pages)

다운로드

(기관인증 필요)

초록보기

Transcatheter arterial chemoembolization (TACE) is a useful palliative therapeutic modality for hepatocellular carcinoma (HCC). Postembolization syndromes, such as fever, abdominal pain, and elevated liver enzyme levels are commonly known complications of TACE. One post-TACE pulmonary complication, lipiodol pneumonitis, is rarely reported. Lipiodol pneumonitis after TACE appears to be associated with chemical injury due to accidental perfusion of lipiodol to the lung vasculature, promoted by arteriovenous shunts within the hypervascular HCC. Here, we report a 42-year-old man with unresectable HCC and hepatic vein thrombosis. The patient was initially treated with TACE. The following day after TACE, acute respiratory symptoms such as dyspnea and cough developed with decreased oxygen saturation. Chest X-ray and computed tomography showed multiple patches and diffuse ground-glass opacities in both lung fields, suggesting of lipiodol pneumonitis. The patient's condition and radiologic abnormalities subsequently improved after 2 weeks of conservative treatment alone. (J Liver Cancer 2020;20:60-66)

KCI등재

8Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review

저자 : Dae Hyun Lim , Jai Hoon Yoon , Dae Won Jun , Oh Young Lee , Byung Chul Yoon , Hang Rak Lee , Kyung Soo Kim , Ho Soon Choi

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 67-71 (5 pages)

다운로드

(기관인증 필요)

초록보기

Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for various malignancies such as unresectable hepatocellular carcinoma, renal cell carcinoma, and gastrointestinal stromal tumors. Several adverse effects have been reported in the literature; however, cardiotoxicity is rare. We present a case of recurrent coronary vasospasm caused by short-term administration (5 days) of sorafenib. Since it caused refractory ischemia after re-administration, we had no choice but to stop the treatment. (J Liver Cancer 2020;20:67-71)

KCI등재

9Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure

저자 : Jaewoong Kim , Jin Won Chang , Jun Yong Park

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 72-77 (6 pages)

다운로드

(기관인증 필요)

초록보기

Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another tyrosine kinase inhibitor, is the only second-line therapy that has been globally approved after progression under sorafenib treatment. Recently, immunotherapeutic agents have emerged as promising treatment options in many different malignancies, including advanced HCC. Nivolumab is the first immunotherapy approved by the Food and Drug Administration for use in HCC patients with advanced-stage second-line after sorafenib failure. In this report, a case of advanced HCC with multiple lung metastases in which a complete response and maintained progression-free status was achieved with nivolumab, following the failure of transarterial chemoembolization and sorafenib is presented. We hope this report may help expand the clinical application of second-line treatment. (J Liver Cancer 2020;20:72-77)

KCI등재

10A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Hepatic Arterial Infusion Chemotherapy and Radiotherapy

저자 : Jin Yong Lee , Jeong-ju Yoo , Seong Joon Chun , Sun Hyun Bae , Jae Myeong Lee , Sang Gyune Kim , Young Seok Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 20권 1호 발행 연도 : 2020 페이지 : pp. 78-83 (6 pages)

다운로드

(기관인증 필요)

초록보기

Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Additionally, hepatic arterial infusion chemotherapy has been used as a treatment option for advanced HCC. Here, we report a case of sustained partial response in a patient with advanced HCC with PVT after hepatic arterial infusion chemotherapy and radiation therapy. (J Liver Cancer 2020;20:78-83)

12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

일산병원 가톨릭관동대학교 인제대학교 성균관대학교 마산대학교
 12
 10
 5
 4
 4
  • 1 일산병원 (12건)
  • 2 가톨릭관동대학교 (10건)
  • 3 인제대학교 (5건)
  • 4 성균관대학교 (4건)
  • 5 마산대학교 (4건)
  • 6 국민대학교 (2건)
  • 7 순천향대학교 (2건)
  • 8 이화여자대학교 (1건)
  • 9 서울교육대학교 (1건)
  • 10 부산대학교 (1건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기